ClinicalTrials.gov
ClinicalTrials.gov Menu

Buprenorphine Formulation Comparison: Sublingual Tablet vs. Solution - 1

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00000320
Recruitment Status : Completed
First Posted : September 21, 1999
Last Update Posted : January 12, 2017
Sponsor:
Information provided by:
National Institute on Drug Abuse (NIDA)

Brief Summary:
The purpose of this study is to compare subject response to liquid vs. tablet formulations, to assess bioequivalency of liquid vs. tablet, to compare subject preference, and to evaluate if dose response curve for tablet is equal to liquid form."

Condition or disease Intervention/treatment Phase
Opioid-Related Disorders Drug: Buprenorphine formulation: liquid vs. tablet Phase 1 Phase 2

Detailed Description:
1) Compare subjects response to liquid vs tablet formulation 2) Assess bioequivalency of liquid vs tablet 3)Compare subject preference 4) Evaluate if dose response curve for tablet = to liquid form

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Buprenorphine Formulation Comparison: Sublingual Tablet vs. Solution
Study Start Date : October 1997
Actual Primary Completion Date : August 1999
Actual Study Completion Date : August 1999

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: 1; liquid formulation
liquid formulation
Drug: Buprenorphine formulation: liquid vs. tablet
random assignment to liquid buprenorphine or tablet buprenorphine
Other Names:
  • Subutex
  • Suboxone

Active Comparator: 2; tablet formulation
tablet formulation
Drug: Buprenorphine formulation: liquid vs. tablet
random assignment to liquid buprenorphine or tablet buprenorphine
Other Names:
  • Subutex
  • Suboxone




Primary Outcome Measures :
  1. blood level [ Time Frame: across study duration ]

Secondary Outcome Measures :
  1. drug use [ Time Frame: across study duration ]
  2. craving [ Time Frame: across study duration ]
  3. withdrawal symptoms [ Time Frame: across study duration ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

M/F ages 18-65. Meet DMS-IV criteria for opiate dependence. Agree to conditions of the study and sign informed consent.

Exclusion Criteria:

Pregnant or nursing women. Acute medical condition that would interfere with study participation or put safety of subjects in jeopardy. Current daily use of anti-convulsants, antabuse or neuroleptics. DSM-IV diagnosis of ETOH or sedative/hypnotics dependence.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000320


Locations
United States, California
Friends Research Institute
Los Angeles, California, United States, 90025
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: Walter Ling, M.D. Friends Research Institute, Inc.

Responsible Party: Walter Ling, M.D., Friends Research Institute
ClinicalTrials.gov Identifier: NCT00000320     History of Changes
Other Study ID Numbers: NIDA-10068-1
R01-10068-1
First Posted: September 21, 1999    Key Record Dates
Last Update Posted: January 12, 2017
Last Verified: January 2009

Keywords provided by National Institute on Drug Abuse (NIDA):
opioid dependence

Additional relevant MeSH terms:
Opioid-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Buprenorphine
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists